O
Orlando Montoya-Herrera
Publications - 5
Citations - 5323
Orlando Montoya-Herrera is an academic researcher. The author has contributed to research in topics: Men who have sex with men & Pre-exposure prophylaxis. The author has an hindex of 5, co-authored 5 publications receiving 4696 citations.
Papers
More filters
Journal ArticleDOI
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
Robert M. Grant,Javier R. Lama,Peter L. Anderson,Vanessa McMahan,Albert Y. Liu,Lorena Vargas,Pedro Goicochea,Martin Casapia,Juan Vicente Guanira-Carranza,Maria Esther Ramirez-Cardich,Orlando Montoya-Herrera,Telmo Fernandez,Valdilea G. Veloso,Susan Buchbinder,Suwat Chariyalertsak,Mauro Schechter,Linda-Gail Bekker,Kenneth H. Mayer,Esper G. Kallas,K. Rivet Amico,Kathleen Mulligan,Lane R. Bushman,Robert J. Hance,Carmela Ganoza,Patricia Defechereux,Brian S. Postle,Furong Wang,J. Jeff McConnell,Jia-Hua Zheng,Jeanny Lee,James F. Rooney,Howard S. Jaffe,Ana Martinez,David N. Burns,David V. Glidden +34 more
TL;DR: Oral FTC-TDF provided protection against the acquisition of HIV infection among the subjects and Detectable blood levels strongly correlated with the prophylactic effect.
Journal ArticleDOI
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Peter L. Anderson,David V. Glidden,Albert Y. Liu,Susan Buchbinder,Javier R. Lama,Juan V. Guanira,Vanessa McMahan,Lane R. Bushman,Martin Casapia,Orlando Montoya-Herrera,Valdilea G. Veloso,Kenneth H. Mayer,Kenneth H. Mayer,Suwat Chariyalertsak,Mauro Schechter,Linda-Gail Bekker,Esper G. Kallas,Robert M. Grant +17 more
TL;DR: PrEP using oral FTC-TDF tablets is a robust intervention for preventing HIV acquisition among men who have sex with men, and specific drug concentrations associated with protection from HIV-1 acquisition in the iPrEx trial are estimated.
Journal ArticleDOI
No Evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis
Julia L. Marcus,David V. Glidden,Kenneth H. Mayer,Albert Y. Liu,Susan Buchbinder,K. Rivet Amico,Vanessa McMahan,Esper G. Kallas,Orlando Montoya-Herrera,José Henrique Pilotto,Robert M. Grant +10 more
TL;DR: There was no evidence of sexual risk compensation in the iPrEx trial, suggesting that risk behavior was not a consequence of PrEP use.
Journal ArticleDOI
Using conjoint analysis to measure the acceptability of rectal microbicides among men who have sex with men in four South American cities.
Janni J. Kinsler,William E. Cunningham,César R. Nureña,Carsten Nadjat-Haiem,Beatriz Grinsztejn,Martin Casapia,Orlando Montoya-Herrera,Jorge Sanchez,Jerome T Galea +8 more
TL;DR: Overall RM acceptability was highest in Guayaquil and lowest in Rio de Janeiro, Brazil, while product effectiveness had the greatest impact on acceptability in all four cities, but the impact of other product characteristics varied by city.
Journal ArticleDOI
Daily Oral Emtricitabine/Tenofovir Preexposure Prophylaxis and Herpes Simplex Virus Type 2 among Men Who Have Sex with Men
Julia L. Marcus,David V. Glidden,Vanessa McMahan,Javier R. Lama,Kenneth H. Mayer,Albert Y. Liu,Orlando Montoya-Herrera,Martin Casapia,Brenda Hoagland,Robert M. Grant +9 more
TL;DR: Tenofovir in daily oral FTC/TDF PrEP may reduce the occurrence of ulcers in individuals with HSV-2 infection but does not protect against HSV -2 incidence among men who have sex with men (MSM).